ArticleJHEP reports : innovation in hepatology2023

Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study.

Marianne Martinello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.